NovaBlog

Timing is Everything: Why Prospective Biospecimen Collection Is Important

Scientists today are increasingly focused on delivering medical innovations tailored to real-world patients. Developing these therapies can be costly, however, and part of the cost can be connected to identifying the right patient sub-population too late in the development process. At Novaseek Research, we aim to drastically reduce the time required to identify the right […]

Read More

The HBS Kraft Precision Medicine Accelerator: A Powerful Voice in Precision Medicine

Last Thursday Novaseek Research had the chance to listen in on the Harvard Business School Kraft Precision Medicine Accelerator Oncology Data Landscape Update call. The Kraft Accelerator was established last year to speed breakthroughs in precision medicine. The Accelerator aims to enable faster commercialization of high-impact innovations by addressing challenges that slow the advancement of […]

Read More

Musings from the Digital Medicine Showcase

Last month I had the opportunity to present Novaseek’s CDNR platform at the second annual Digital Medicine Showcase. This event is a part of the Biotech Showcase event that takes place during the J.P. Morgan Annual Healthcare Conference. Digital Medicine Showcase brings together innovative companies and gives them a forum to present their clinically impactful […]

Read More

Leveraging the Power of Data: The Role of Patient Consent and Efficiency

Last month, Foundation Medicine and Flatiron Health announced an initiative to assemble large genomic databases built around the electronic health records (EHRs), of 20,000 cancer patients. The purpose of this initiative would be to provide a real world data-based tool for oncology reseachers. It’s exciting to think about the possibilities that this type of database […]

Read More

Aligning Drug Development to More Accurately Reflect the Real-World Patient

With the advance of precision medicine, ensuring that clinical studies more accurately reflect real-world patients needs to be at the heart of drug discovery and development. Historically, one of the reasons that so many studies fail is because patient cohorts are often not defined optimally for the treatment being investigated. Step one in changing this […]

Read More

How Researchers at Biopharma Companies and Academia Can Gain Better Insights into Real-World Clinical Phenotype Data To Improve Clinical Development

Precision medicine is an exciting area of innovation for researchers in academia and industry. It holds the promise of better outcomes for patients, and it is changing the way patients experience disease and treatment. By definition, the patient population for a targeted medicine is smaller than that of the disease category as a whole. Medicines affect patients differently.1 […]

Read More

Visit Novaseek at 2016 AAPS National Biotechnology Conference (May 16-18) at the Sheraton Boston Hotel.

The 2016 AAPS National Biotechnology Conference is the ideal venue to showcase Novaseek’s novel Clinical Data Network for Research (CDNR) platform for accessing the clinical data and biospecimens for research. Please visit us at Booth 403 and learn how Novaseek’s CDNR platform can inform your experiments and biospecimen requests with real world patient phenotype data, […]

Read More

Patients as Partners – Why Biospecimen Consent Matters

We have received many emails about a recent Op-Ed in the New York Times – “Your Cells. Their Research. Your Permission?” By Rebecca Skloot (Dec. 30, 2015). In her piece, Ms. Sloot correctly points out that patient consent is a significant issue regarding the use of biospecimens in research: “Tissues from millions of Americans are […]

Read More

The EHR: Where medicine now takes place

Illinois-based NorthShore University HealthSystem, along with Dartmouth, University of Pennsylvania, Wake Forest Baptist Health System, Medical University of South Carolina, Ochsner Health System, University of Arkansas, and the University of Nebraska are collaborating on “to precision medicine at the point of care, through the EMR.” Focused on neurological disease, this consortium of leading hospitals is […]

Read More

Biosamples exchanges – the past, the current and the future – how do we make it work?

  In today’ age of personalized medicine, getting “fit for purpose” biosamples is crucial for pharmaceutical industry. Creating solutions that meet this objective was the topic of a webinar recently put on by the Pistoia Alliance. Dr. Kate Torchilin, CEO of Novaseek, moderated the discussion: http://www.pistoiaalliance.org/slides-available-from-biosample-exchanges-webinar/ According the expert panel, the biobank industry today is […]

Read More